Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Healthy You
    • Job listings
    • Q&As
    • Special sections
  • Multimedia
    • Quiz
    • Podcasts
    • Videos
  • FAQs
    • Advertising
    • Subscriptions
    • For APHA members
    • Internships
    • Change of address
  • About
    • About The Nation's Health
    • Submissions
    • Permissions
    • Purchase articles
    • Join APHA
  • Contact us
    • Feedback
  • APHA
    • AJPH
    • NPHW

User menu

  • My alerts

Search

  • Advanced search
The Nation's Health
  • APHA
    • AJPH
    • NPHW
  • My alerts
The Nation's Health

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Healthy You
    • Job listings
    • Q&As
    • Special sections
  • Multimedia
    • Quiz
    • Podcasts
    • Videos
  • FAQs
    • Advertising
    • Subscriptions
    • For APHA members
    • Internships
    • Change of address
  • About
    • About The Nation's Health
    • Submissions
    • Permissions
    • Purchase articles
    • Join APHA
  • Contact us
    • Feedback
  • Follow The Nation's Health on Twitter
  • Follow APHA on Twitter
  • Visit APHA on Facebook
  • Follow APHA on Youtube
  • Follow APHA on Instagram
  • Follow The Nation's Health RSS feeds
NewsWeb-only News

Online-only: Report gives FDA an ethical framework for studies of approved drugs

Donya Currie
The Nation's Health September 2010, 40 (7) E31;
Donya Currie
  • Search for this author on this site

When deciding whether to require post-marketing studies of approved drugs, the U.S. Food and Drug Administration should follow an ethical framework to ensure study participants fully understand health risks, according to a recent Institute of Medicine report.

The report, released in early July just as safety concerns were halting studies of the diabetes drug Avandia because of links to severe heart risks, also said FDA officials should make sure the post-marketing studies themselves are ethically conducted.

“Particularly in research settings in which participants have low literacy, low income and poor access to modern health care and medicines, even a robust consent process may do little to countervail the pressures that lead people to participate in research,” according to the report, which was authored by the IoM Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs.

The report came in response to a request by FDA Commissioner Margaret Hamburg, MD, for a study on scientific and ethical issues involved in post-marketing drug safety research. Hamburg’s request to the IoM was part of FDA’s response to a critical Senate Finance Committee report, released in February, on the safety of Avandia, a brand name drug for the type 2 diabetes medication rosiglitazone.

So-called “black box” warnings on drug packaging have come under scrutiny in recent years, including those advising that certain antidepressants may up the risk for suicide. In mid-July, an FDA panel voted to add cardiovascular risk factors to Avandia’s label. One question is whether drugs requiring such strong warnings should be on the market at all.

On July 22, GlaxoSmithKline suspended enrollment of new patients into an Avandia post-marketing trial at FDA’s request. The trial compared the cardiovascular safety of Avandia and the drug Actos in patients with type 2 diabetes.

The IoM report said during the informed consent process prior to drug research studies, the emphasis placed on risk information should rise both with the severity of risk and with how much certainty exists about how the drug causes the adverse outcome, which in the case of Avandia is congestive heart failure and heart attack.

“At a minimum, risks that should be disclosed should include any black box warnings, the ’major statement’ currently listed in television advertisements, any adverse event findings of an FDA advisory committee, and a summary of evidence from published peer-reviewed studies,” according to the IoM report.

The report recommended that, in addition to verbal disclosures and written consent documents, potential study participants should have access to additional tools such as videos and interactive electronic presentations to make possible risks clear.

“Whatever efforts are employed to communicate with potential participants, it is key that they include information that is useful to participants about where the weight of the evidence falls with regard to serious risks and the level of confidence that experts have in drawing conclusions about the risks,” according to the report. “A statement that ’some studies have found that the drug causes X, whereas others have not’ may be true, but misleading if nearly all well-designed studies have reached the same conclusion and there is little or no reliable evidence on the other side.”

The IoM report did not delve into the specifics of the Avandia case or go in depth about issues related to the ethical and scientific justifications of clinical trials. The authoring committee is scheduled to issue a final, more comprehensive report in 2011.

The “Ethical Issues in Studying the Safety of Approved Drugs: A Letter Report” is online at www.nas.edu.

    • Copyright The Nation’s Health, American Public Health Association
    PreviousNext
    Back to top

    In this issue

    The Nation's Health: 40 (7)
    The Nation's Health
    Vol. 40, Issue 7
    September 2010
    • Table of Contents
    • Table of Contents (PDF)
    • Index by author
    • Complete Issue (PDF)

    Healthy You

    Healthy You

    Print
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article
    We do not capture any email addresses.
    Enter multiple addresses on separate lines or separate them with commas.
    Online-only: Report gives FDA an ethical framework for studies of approved drugs
    (Your Name) has sent you a message from The Nation's Health
    (Your Name) thought you would like to see this item on The Nation's Health website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Online-only: Report gives FDA an ethical framework for studies of approved drugs
    Donya Currie
    The Nation's Health September 2010, 40 (7) E31;

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Online-only: Report gives FDA an ethical framework for studies of approved drugs
    Donya Currie
    The Nation's Health September 2010, 40 (7) E31;
    del.icio.us logo Twitter logo Facebook logo Mendeley logo
    Tweet Widget Facebook Like LinkedIn logo

    Jump to section

    • Top

    More in this TOC Section

    • Newsmakers: May 2025
    • Newsmakers: April 2015
    • Newsmakers: February/March 2025
    Show more Web-only News

    Popular features

    • Healthy You
    • Special sections
    • Q&As
    • Quiz
    • Podcasts

    FAQs

    • Advertising
    • Subscriptions
    • For APHA members
    • Submissions
    • Change of address

    APHA

    • Join APHA
    • Annual Meeting
    • NPHW
    • AJPH
    • Get Ready
    • Contact APHA
    • Privacy policy

    © 2025 The Nation's Health

    Powered by HighWire